Skip to main content
Journal cover image

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.

Publication ,  Journal Article
Guimarães, PO; Peterson, ED; Stevens, SR; Lokhnygina, Y; Green, JB; McGuire, DK; Holman, RR; Lopes, RD
Published in: Int J Cardiol
August 15, 2019

BACKGROUND: We investigated the use of different antithrombotic therapies at baseline among patients with a history of atrial fibrillation (AF), type 2 diabetes, and established atherosclerotic cardiovascular disease (ASCVD) enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: TECOS participants with a history of AF were stratified by CHA2DS2-VASc score and their antithrombotic use evaluated. Cox proportional hazards models were employed to explore possible associations between history of AF and prespecified clinical outcomes after adjusting for key baseline characteristics. RESULTS: Of the 14,671 TECOS participants, 1167 (8%) had a history of AF, of whom 51.6% were using vitamin K antagonists (VKA); 31.2% used VKA alone, 16.9% used aspirin plus VKA, 1.8% used clopidogrel plus VKA, and 1.7% used aspirin and clopidogrel plus VKA. Aspirin was used by 56.8%: 30.9% used aspirin alone and 7.3% aspirin plus clopidogrel. Clopidogrel alone was used by 2.9%, and 7.3% were not using any antithrombotic medication. Participants with a history of AF had a higher risk of cardiovascular events, including hospitalization for heart failure and all-cause mortality, than those without AF. White, older men with prior myocardial infarction, heart failure, peripheral artery disease, or prior stroke were more likely to develop new-onset AF than others without these characteristics. CONCLUSIONS: Almost half of high-risk AF patients with diabetes and established ASCVD in TECOS were not treated with anticoagulation therapy despite clear guideline recommendations for such therapy, highlighting the challenge and potential for clinical improvements in managing these patients in clinical practice. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

August 15, 2019

Volume

289

Start / End Page

58 / 62

Location

Netherlands

Related Subject Headings

  • Vitamin K
  • Treatment Outcome
  • Time Factors
  • Stroke
  • Sitagliptin Phosphate
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Guimarães, P. O., Peterson, E. D., Stevens, S. R., Lokhnygina, Y., Green, J. B., McGuire, D. K., … Lopes, R. D. (2019). Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. Int J Cardiol, 289, 58–62. https://doi.org/10.1016/j.ijcard.2019.04.085
Guimarães, Patrícia O., Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, and Renato D. Lopes. “Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.Int J Cardiol 289 (August 15, 2019): 58–62. https://doi.org/10.1016/j.ijcard.2019.04.085.
Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, et al. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. Int J Cardiol. 2019 Aug 15;289:58–62.
Guimarães, Patrícia O., et al. “Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.Int J Cardiol, vol. 289, Aug. 2019, pp. 58–62. Pubmed, doi:10.1016/j.ijcard.2019.04.085.
Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. Int J Cardiol. 2019 Aug 15;289:58–62.
Journal cover image

Published In

Int J Cardiol

DOI

EISSN

1874-1754

Publication Date

August 15, 2019

Volume

289

Start / End Page

58 / 62

Location

Netherlands

Related Subject Headings

  • Vitamin K
  • Treatment Outcome
  • Time Factors
  • Stroke
  • Sitagliptin Phosphate
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Humans